Global Hereditary Angioedema Market: Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2030

 

                                                Hereditary Angioedema Market

Associated with the immune system, hereditary angioedema (HAE) is a rare condition. Lack of C1-esterase inhibitor (C1-INH), which causes the blood vessels to enlarge, results in a life-threatening disorder. Recurrent episodes of edoema in different body areas, such as the hands, feet, face, and airways, are among the signs of the illness. Based on the decrease in inhibitor production or the development of an abnormal protein, HAE is divided into three types: Type I HAE, Type II HAE, and Type III HAE. Although the disorder is inherited, a diagnosis of HAE should not be made in the absence of a family history, according to research showing that up to 25% of HAE cases are the result of a spontaneous mutation of the C1-inhibitor gene at conception.

Low levels or inappropriate operation of a protein known as the C1 inhibitor result in hereditary angioedema (HAE). Blood vessels are impacted by it. Rapid swelling of the face, larynx (voice box), limbs, hands, feet, and other body parts can occur during an HAE incident (windpipe). Hereditary Angioedema Market

is a very uncommon hereditary condition that is often characterized by edema (swelling) in several body areas, including the neck (airways), feet, cheeks, and hands.

Family history is the primary determinant of Hereditary Angioedema Market

risk, and in 50% of cases, a child may receive the illness from one or both of his or her parents. Although the absence of family history may result in lower risks, it does not entirely exclude the illness because it can also happen owing to a genetic mutation.

Increased Hereditary Angioedema Market options, rising diagnoses as a result of diagnostic advances, rising instances of the genetic mutations that cause the disorder, and a sizable portion of unmet clinical needs are anticipated to propel the growth of the hereditary angioedema treatment market over the course of the forecast period.

Key Players

A few of the major companies competing in the global hereditary angioedema market are CSL Behring, Takeda Pharmaceutical Company Limited, Pharming, BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.